Related Experiment Video
Updated: Jul 19, 2025
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer
Fatemeh Davoudi1,2, Afshin Moradi1,3,4, Therese M Becker5
1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia.
Current Treatment Options in Oncology
|August 10, 2023
Summary
Advanced prostate cancer (PCa) management can be improved by discovering new prognostic and treatment predictive biomarkers. This enhances personalized medicine, reduces mortality, and improves quality of life for patients.
Area of Science:
- Oncology
- Genetics
- Biomarker Discovery
Background:
- Prostate cancer (PCa) is a leading cause of cancer death in men, with limited personalized therapeutic strategies due to disease heterogeneity.
- Advances in screening and treatment exist, but optimal personalized approaches require better diagnostic and prognostic tools.
Purpose of the Study:
- To review current and emerging biomarkers for advanced prostate cancer (PCa).
- To discuss the clinical implications of genomic aberrations and phenotypic biomarkers for diagnosis, prognosis, and treatment prediction.
- To explore the potential of these biomarkers in guiding precision medicine for advanced PCa.
Main Methods:
- Review of polygenic risk scores for PCa screening.
- Analysis of common genomic aberrations in AR, PTEN-PI3K-AKT, and DDR pathways.
- Evaluation of liquid biopsy, protein biomarkers (serum testosterone, SLFN11, tALP, NLR), tissue biopsy, and advanced imaging.
Main Results:
- Genomic aberrations and phenotypic biomarkers show potential for diagnosis, prognosis, and treatment prediction in advanced PCa.
- Liquid biopsy, protein markers, and imaging tools are being evaluated for improved utilization.
- Integration of genotypic and phenotypic methods supports informed treatment decisions.
Conclusions:
- Prognostic and treatment predictive biomarker discovery is crucial for improving advanced PCa management, especially in metastatic stages.
- Enhanced biomarker utilization can decrease mortality and improve quality of life.
- Personalized treatment regimens can be designed through advanced biomarker strategies.
